Nontuberculous Mycobacteria
9
2
3
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
11%
1 trials in Phase 3/4
33%
1 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
Mycobacterial and Opportunistic Infections in HIV-Negative Thai and Taiwanese Patients Associated With Autoantibodies to Interferon-gamma
Evaluation Of The Lung Microbiome In NTM Bronchiectasis
Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at Home
Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections
Exercise Intervention in Patients With Nontuberculous Mycobacterial Pulmonary Disease
State of Play of Non-tuberculous Mycobacteria in Alsace
Treat Early and Broad: Thermotherapy of Buruli Ulcer Integrated Into WHO-recommended Wound Management in West Africa
The Italian REgistry of Pulmonary Non-tuberculous mycobactEria
Clarithromycin for the Treatment of Infections Caused by Nontuberculous Mycobacteria (NTM)